2023年第46届圣安东尼奥乳腺癌研讨会（San Antonio Breast Cancer Symposium，SABCS）将于12月5日至9日在美国得克萨斯州圣安东尼奥举行。该会议汇聚了全球约1万名临床医生和专家，是规模最大、最具影响力的乳腺癌研究盛会。
日前，大会公布了本次会议的详细日程及研究题目，150余项中国研究成果入选SABCS POSTER session。【肿瘤资讯】从官网获得现有资讯，将入选POSTER session 4的中国研究信息整理如下，以飨读者。
PO4-01-13 Effect of interruption or discontinuation of endocrine therapy on the prognosis of breast cancer patients: a cohort study using the real-world database.
作者：Ya Huang，Jie Chen，Yunhao Wu
第一作者单位：West China Hospital，Sichuan University, Chengdu, China
PO4-04-01 Antitumor activity and safety of sacibertinib (Hemay022) in combination with endocrine therapy in patients with ER and HER2 both positive metastatic breast cancer: A phase Ib study.
作者：Hui- Ping Li，Qingyuan Zhang，Ruyan Zhang，Yaxin Liu，Xianjun Hu
第一作者单位：Department of Medical Oncology, Peking University Cancer Hospital & Institute, China (People's Republic)
PO4-04-02 Real-world first line use of trastuzumab biosimilar (HLX02), pertuzumab and chemotherapy for Chinese patients with HER2-positive metastatic breast cancer.
作者：Ruyan Zhang，Guohong Song，Xiaoran Liu，Hui-Ping Li
第一作者单位：Department of Breast Oncology, Peking University Cancer Hospital & Institute
PO4-04-04 A Multicenter, Retrospective, Real World Study of Inetetamab Combined with Pyrotinib and Vinorelbine as Treatment for HER2-positive Metastatic Breast Cancer.
作者：Yongmei Yin，Wei Li，Xiang huang，Nan Jin，Xinyu Wu，Chunxiao Sun，Yijia Hua
第一作者单位：The First Affiliated Hospital of Nanjing Medical University
PO4-04-06 Exploring the use of tyrosine kinase inhibitors (TKIs) in the management of HER2-positive metastatic breast cancer post trastuzumab emtansine (T-DM1) therapy failure: Insights from a real- world study.
作者：Yongmei Yin，Chunxiao Sun，Yijia Hua，Nan Jin，Wei Li，Xiang huang
第一作者单位：The First Affiliated Hospital of Nanjing Medical University
PO4-04-07 Efficacy, safety and translational study of pyrotinib combined with albumin-bound paclitaxel as firstline treatment of HER-2 positive metastatic breast cancer.
作者：huihui Li，Xiaochu Man ，Sha Yin，Dongdong Zhou，Baoxuan Zhang，Shu Fang，fangchao zheng，Chao Li，Xinzhao Wang，Wei Huang，Linlin Wang，Qingqing He，Hui Fu，Yan Zhang，Changrui Liu，Lin Dong，Xianguang Zhao，Liang Xu，Xiao Sun，Bingjie Fan，Lihua Song，zhengbo zhou，Qiaorui Tan，Jinming Yu
第一作者单位：Department of Breast Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, China (People's Republic)
PO4-05-04 Comparative effectiveness of Palbociclib plus Aromatase inhibitor versus fulvestrant alone as initial endocrine therapy for HR+/HER2- advanced breast cancer in Chinese clinical practice: a real- world study.
作者：Jian Yue，xue Wang，Jie Ju，Zixiang Yang，Tong Wei，Peng Yuan，Min Gao ，Ling Xu，Yin Guan
第一作者单位：National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
PO4-05-08 Primary endocrine therapy resistance in patients with de novo HR+/HER2- metastatic breast Cancer: a National Cancer Information Database Analysis in China.
作者：Zhanhong Chen，Xiying Shao，Yabing Zheng，Wenming Cao，junqing chen，Weizhu Wu，Ting Wang，Xiaojia Wang
第一作者单位：Department of Medical Oncology (Breast), Zhejiang Cancer Hospital
PO4-05-10 A Carryover Effect: Antibody Drug Conjugates Constantly Provide a Substantial Improvement in Overall Survival more than in Progression-free Survival.
作者：I-Chun Chen，Ching-Hung Lin，Yen-Shen Lu
第一作者单位：Department of Medical Oncology, National Taiwan University Cancer Center
PO4-07-04 Breast Cancer HER2 Status Prediction from Hematoxylin-Eosin Stained Images Using Point Cloud Transformer.
作者：Bao Li，Zhenyu Liu，Yang Du，Jie Tian
第一作者单位：CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, China (People's Republic)
PO4-08-01 Methylsterol monooxygenase 1 ( MSMO1) modulates endoplasmic reticulum stress through cholesterol metabolic reprogramming to alter chemotherapy sensitivity in breast cancer.
作者：Hengyu Ren，Liren Wangxu，Yayun Chi，Jiong Wu
第一作者单位：Fudan University Shanghai Cancer Center，Shanghai，China. Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China
PO4-10-07 Understanding Psychological distress in patients prior to breast cancer diagnosis：Mixed Methods Study.
作者：Yan Gao，Jinnan Gao
第一作者单位：Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University
PO4-10-08 Building a standard methodology: Early Gynecologic Consultation and Bone Mass Density Examination in Breast Cancer Patients Receiving Endocrine Therapy.
作者：Chiu Ching-Wen，Tam Ka-Wai ，Su Chih-Ming，Wu Hsueh-Chi
第一作者单位：Taipei Medical University
PO4-13-09 Paclitaxel affects the efficacy of PD-1 blockade by interfering with lipid metabolism reprogramming in patients with breast cancer.
作者：Hongnan Mo，Jiashu Han，Jingtong Zhai，Xiaoying Sun，Xiuwen Guan，Haili Qian，Fei Ma
第一作者单位：National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China (People's Republic)
PO4-16-05 Identification of functional HLA-A*11:01-restricted driver gene PIK3CA mutation specific T- cell receptors.
作者：Meiying shen，Xiaojian han，siyin chen，aishun jin，Shengchun Liu
第一作者单位：Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University
PO4-18-03 Combined Treatment with Pyrotinib and Chrysin Synergistically Improve the Autophagy Level in HER2-Positive Breast Cancer by Regulating the miR-16-5p/ZBTB16/G6PD Axis.
作者：Ting Luo，Xiaorong Zhong，Ping he，Dan Zheng，Yan Cheng，Kunrui Zhu
第一作者单位：Department of Medical Oncology，Cancer Center, West China Hospital, Sichuan University
PO4-18-04 An exploratory study of Trastuzumab Deruxtecan neoadjuvant therapy in HER2-positive or HER2-low early or locally advanced breast cancer after a poor response to neoadjuvant chemotherapy.
作者：Jin Zhang，Zhendong Shi，Jingjing Liu
第一作者单位：The 3rd Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin 300060, China, Tianjin, China (People's Republic)
PO4-20-02 A prospective, randomized, controlled clinical trial comparing different PEG-rhG-CSF administration times to treat chemotherapy-induced neutropenia and febrile neutropenia in early breast cancer.
作者：Xiaoming Zha，Jue Wang，Yinggang Xu，Jinzhi He，Ye Wang，Weiwei Zhang ，Xinyu Wan，Wenjie Shi
第一作者单位：the First Affiliated Hospital of Nanjing Medical University
PO4-22-11 Study to Compare the Safety of Immediate One-stage IBBR With Expander-Implant Two- stage IBBR Augmented With TiLoop® Bra(COSTA).
作者：Benlong Yang，Jian Liu，Haibo Wang，Yiding Chen，Cuizhi Geng，Nanyan Rao，Siyuan Han，Antai Zhang，Jinping Shi，Qiang Zhang ，Wenhe Zhao，Jiong Wu
第一作者单位：Fudan University Shanghai Cancer Center, Shanghai, China, Shanghai, China (People's Republic);
PO4-23-04 Is breast-conserving surgery an optional local therapy for non-inflammatory skin involvement (T4b) breast cancer? A Propensity Score Matching and Inverse Probability Weighting Analysis of SEER Database Results.
作者：Jingyi Lin，Shiping luo，Jie Zhang，Chuangui Song
第一作者单位：Fujian Medical University Union Hospital, China (People's Republic)
PO4-25-02 Long-range Deployment of Tumor-antigen Specific Cytotoxic T Lymphocytes Inhibits Lung Metastasis of Breast Cancer.
作者：Yue Xing，Shicheng Su，Erwei Song
第一作者单位：Sun Yat-Sen Memorial Hospital
PO4-26-08 Prevalence of HER2-low and IHC >0 to 1+ in breast cancer and its concordance between historical and rescored results: a multi-center, retrospective study in China.
作者：Hong Lv，Junqiu Yue，Qingfu Zhang， Fangping Xu，Jianming Li，Lingfei Kong，Peng Gao，Guanjun Zhang，Haifeng Yang，Xiu Nie ， Wen-Tao Yang
第一作者单位：Fudan University Shanghai Cancer Center
PO4-26-09 The Advantage of Artificial-Intelligence in HER2 IHC 0 and 1+ Scoring in Breast Cancer.
作者：Ming Li，Hong Lv，Yizhi Zhao，Chenglu Zhu，Hansheng Li，Mingzhen Lin，Wen-Tao Yang
第一作者单位：Fudan University Shanghai Cancer Center
PO4-27-05 A phase I open-label dose escalation trial of FWD1802 as monotherapy and in combination with palbociclib in patients with ER+/HER2- unresectable locally advanced or metastatic breast cancer with or without ESR1 mutations.
作者：Ling Zeng，Jin Liu，Dan Wu，Huiwen Ge，Zirui Bian，Chenggang Zhu
第一作者单位：Shenzhe Forward Pharmaceuticals Co. Ltd., China (People's Republic).
PO4-28-07 SLC26A9 promotes triple-negative breast cancer progression by regulating lipid metabolism.
作者：Yingming Zhou，Hu Wang，Zhengxing Zhou，Xuemei Liu，Biguang Tuo，Taolang Li
第一作者单位：Department of General Surgery, Affiliated Hospital of Zunyi Medical University
SABCS中国之声总览：
Rapid Fire Session: Mini-Oral Presentations、POSTER SPOTLIGHT Session
排版编辑：肿瘤资讯-张薪媛
苏公网安备32059002004080号
